After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Piper Sandler expressed continued confidence in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintaining an Overweight ...

Bernstein SocGen Group adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. With a ...

Flash-Lite 2 can generate captions for around 40,000 unique images at a cost of less than a dollar on Google AI Studio’s paid ...

The focus of Wall Street investors in the week ahead will be primarily on expected reciprocal trade tariffs by US President ...

RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis ... Symkevi has been an option for CF patients in this group aged 12 or over for two years, but the new approval ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis ... campaign is particularly welcome,” said patient group CF Voices. “Patients shouldn’t have to lobby, beg ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...